Wegovy vs. Zepbound: What's the Difference?

Short answer: Wegovy (semaglutide) activates one hormone receptor; Zepbound (tirzepatide) activates two. That extra pathway tends to produce more weight loss in Zepbound's favor, but Wegovy currently holds an FDA cardiovascular-risk approval that Zepbound doesn't yet have — and Wegovy now comes in a daily pill, not just a weekly injection.

Both of these medications get compared constantly because they occupy the same space: FDA-approved, once-weekly injectable treatments for chronic weight management. But they're different drugs with different mechanisms, different approval histories, and — as of recent FDA actions — different available formulations. Here's what the data actually shows.

Different Drugs, Same Goal

Wegovy is the brand name for semaglutide, a GLP-1 receptor agonist.^[1]Zepbound is the brand name for tirzepatide, a dual GLP-1/GIP receptor agonist — meaning it activates a second hormone receptor (GIP) that Wegovy doesn't touch at all.^[2]

Both are approved by the FDA as an adjunct to reduced-calorie diet and increased physical activity for adults with obesity (BMI ≥30) or overweight (BMI ≥27) who also have at least one weight-related health condition.^[1][2] Wegovy is additionally approved for adolescents 12 and older with obesity.^[1]

How the Formulations Have Expanded

As of 2026, Wegovy is available in three forms:

• Wegovy injection — the original once-weekly 2.4 mg subcutaneous injection
• Wegovy HD — a higher-dose 7.2 mg weekly injection, approved in 2026 for additional weight loss beyond the standard dose
• Wegovy pill — a once-daily 25 mg oral tablet, approved in late 2025 as the first FDA-approved oral semaglutide for weight management

Zepbound, by contrast, is currently available only as a once-weekly injection, in dose strengths ranging from 5 mg to 15 mg. There's no FDA-approved oral tirzepatide formulation. If a daily pill instead of a weekly injection matters to you, that's currently a Wegovy-only option among these two brands — though Foundayo (orforglipron) is another oral GLP-1 option approved in 2026.^[7]

Which One Produces More Weight Loss?

This is where the mechanism difference shows up directly in the data.

In STEP-1, weekly semaglutide 2.4 mg produced a mean −14.9% change in body weight at 68 weeks (vs. −2.4% with placebo).^[3] In SURMOUNT-1, tirzepatide 15 mg produced a mean −20.9% change at 72 weeks (vs. −3.1% with placebo), with a large share of participants losing ≥20% of starting weight at the highest dose.^[4]

The direct head-to-head comparison is SURMOUNT-5 (Aronne et al., NEJM): over 72 weeks in 751 adults, tirzepatide produced a mean −20.2% weight change versus −13.7% with semaglutide at maximum approved doses — roughly 50 lb vs. 33 lb on average.^[5] Broader cross-trial comparisons have similarly reported more average weight loss with higher-dose tirzepatide than with approved-dose semaglutide, though those estimates are less precise than a dedicated head-to-head trial.

The Cardiovascular Difference — Wegovy's Current Edge

This is a meaningful distinction that often gets missed in side-by-side comparisons: Wegovy has an FDA-approved cardiovascular risk-reduction indication that Zepbound does not currently have.^[1][2]

Wegovy's cardiovascular approval is based on the SELECT trial — a large outcomes study of over 17,000 adults with overweight or obesity and established cardiovascular disease, but without diabetes. SELECT used weekly injectable semaglutide 2.4 mg and found roughly a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) compared to placebo.^[6]Based on this data, Wegovy's current labeling carries an approved indication for reducing cardiovascular risk in adults with obesity or overweight who already have heart disease — and that indication applies to both the injection and the oral tablets, even though SELECT itself was an injectable outcomes trial.^[1]

Zepbound's current labeling is focused on chronic weight management. As of its most recent FDA label, it does not yet carry a separate cardiovascular outcomes approval, though SURMOUNT trial data has shown improvements in related cardiometabolic markers like blood pressure and lipids, and further outcome studies are ongoing.^[2]

Practically: if cardiovascular risk reduction alongside weight loss is a specific priority — particularly for someone who already has diagnosed heart disease — that's currently a distinction in Wegovy's favor at the regulatory level, independent of which drug produces more weight loss on average.

Side Effects: Still Mostly the Same Story

As with other GLP-1 and dual-agonist comparisons, the side effect profiles of Wegovy and Zepbound are dominated by the same gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion are the most commonly reported effects for both. Both carry the same boxed warning for thyroid C-cell tumors seen in animal studies and are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.^[1][2]

Both labels also carry warnings for pancreatitis, gallbladder disease, and acute kidney injury (often related to dehydration from GI symptoms). Zepbound's label additionally notes a hypoglycemia risk when combined with insulin or certain other diabetes medications.^[2]

In SURMOUNT-5, discontinuation for adverse events was in a similar range for both arms (about 6% with tirzepatide vs. 8% with semaglutide), so Zepbound's edge in average weight loss does not clearly come with meaningfully worse overall tolerability — though individual GI experience still varies widely.^[5]

Dosing and Titration

Both medications start well below their target dose and increase gradually:

Wegovy injection

Starts at 0.25 mg weekly, increasing every 4 weeks (0.5 mg → 1.0 mg → 1.7 mg) to the 2.4 mg maintenance dose. Wegovy HD follows a similar escalation pattern toward the higher 7.2 mg dose.^[1]

Wegovy pill

Starts at 1.5 mg once daily, increasing roughly every 30 days through intermediate doses (4 mg, then 9 mg) toward the 25 mg daily maintenance dose.^[1]

Zepbound

Starts at 2.5 mg weekly, increasing in 2.5 mg increments roughly every 4 weeks (5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg) toward the target maintenance dose.^[2]

The exact pace — and whether to hold at a lower dose longer — is a decision a prescriber makes based on how well someone tolerates each increase.

Practical Differences Worth Knowing

• Administration:Both injectable versions use prefilled devices, require refrigerated storage (with limited room-temperature allowances), and are injected in the abdomen, thigh, or upper arm. The Wegovy pill doesn't require refrigeration and is taken orally once daily.
• Formulation choice:If a daily pill over a weekly injection is a meaningful preference for you, that's currently available only through Wegovy among these two brands.
• A third option now exists:Foundayo (orforglipron), approved in April 2026, is a once-daily oral GLP-1 pill from Eli Lilly that's chemically different from both semaglutide and tirzepatide — worth knowing about if you're specifically comparing pill options.^[7] See our full Foundayo comparison for details.
• Cardiovascular history:If you have established cardiovascular disease alongside obesity or overweight, Wegovy's SELECT-trial-based approval is a specific, documented indication that Zepbound doesn't currently carry — and the label extends that indication to the oral tablets as well as the injection.^[1][6]
• Regulatory pace matters here:Both drugs have seen their approved formulations and indications expand significantly in the past two years — Wegovy's HD dose and oral pill are both recent additions, and Zepbound's label continues to be updated as new trial data comes in. Whatever comparison you're reading, including this one, is worth checking against the current FDA label before making a decision, since this is a genuinely fast-moving area of drug approval.

Frequently Asked Questions

See also: Semaglutide vs. Tirzepatide · Foundayo vs. Semaglutide vs. Tirzepatide · Oral vs. Injectable GLP-1 · Shop brand-name GLP-1 prices